This article is for educational and research purposes only. AOD-9604 and Tesamorelin are not approved treatments for weight loss in Australia. Semaglutide is a prescription medicine requiring medical supervision. Nothing in this article constitutes medical advice. Consult a qualified medical practitioner before considering any weight management intervention.
The term "peptide weight loss stack" has become increasingly common in both research literature and consumer health discussions — but it bundles together compounds that differ substantially in their mechanisms, regulatory status, evidence base, and appropriate use context. Understanding what AOD-9604, Tesamorelin, and Semaglutide actually are, what each does at a biological level, and how they compare to one another is the starting point for any informed discussion of this field.
This article provides a research-focused overview of all three, situating them within the current Australian regulatory and scientific landscape.
Peptides are short chains of amino acids — the same building blocks as proteins, but in smaller, more specific sequences. Biological peptides function as signalling molecules: they bind to receptors and trigger specific cellular responses. Because they are highly targeted, peptides have attracted significant pharmaceutical research interest for applications ranging from diabetes and metabolic disease to growth hormone disorders and obesity.
The three compounds most commonly discussed in the context of a "peptide weight loss stack" represent three distinct biological approaches to the same underlying problem — excess adipose tissue — operating through very different mechanisms:
Understanding that these are mechanistically distinct — not variations on the same theme — is essential to interpreting both the research and the regulatory picture.
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide derived from the C-terminus of human growth hormone (hGH), specifically the amino acid sequence at positions 176–191 of the hGH molecule. It was developed by Australian researchers at Monash University in the 1990s with the explicit goal of isolating the fat-metabolising properties of hGH without the anabolic (muscle-building) and insulin-sensitising effects of the full growth hormone molecule.
Full hGH has significant metabolic effects on both fat and muscle. It stimulates lipolysis (fat breakdown), promotes muscle protein synthesis, affects blood glucose, and influences IGF-1 levels throughout the body. AOD-9604 was designed around the hypothesis that the fat-specific actions of hGH resided primarily in a discrete region of the molecule — and that isolating that fragment might produce a compound with targeted anti-obesity effects without the broader hormonal disruption of exogenous full hGH.
For a detailed examination of the underlying science, see our dedicated article on AOD-9604 as an anti-obesity peptide and the closely related HGH Fragment 176-191 overview.
AOD-9604 is thought to work through two primary pathways:
1. Lipolysis stimulation: The peptide appears to stimulate the breakdown of stored triglycerides in adipose tissue, releasing free fatty acids into circulation for use as energy substrate. This mirrors one component of full hGH's metabolic action without the broader endocrine effects.
2. Lipogenesis inhibition: In addition to promoting fat breakdown, AOD-9604 research has examined its potential to inhibit new fat storage by reducing the conversion of carbohydrate substrates into lipids — a process called de novo lipogenesis.
Critically, AOD-9604 does not appear to significantly affect growth hormone receptor signalling in the same way as full hGH, and does not produce the insulin resistance or IGF-1 elevation associated with full growth hormone administration. This selectivity was the core design objective.
AOD-9604's research history is unusual: it proceeded far enough through clinical development to enter Phase IIb human trials before stalling. The timeline:
The compound achieved GRAS (Generally Recognised As Safe) status from the US FDA in 2014 for use as a food ingredient — an unusual designation that reflects the safety data accumulated rather than clinical approval for therapeutic use.
Important context: The preclinical data for AOD-9604 is more robust than the human clinical data. Translating rodent obesity model results to human outcomes is notoriously unreliable — a limitation that has frustrated obesity drug development broadly. The clinical evidence for AOD-9604 as a standalone weight loss intervention in humans is currently insufficient to support therapeutic recommendations.
AOD-9604 is not TGA-approved as a therapeutic product for weight loss in Australia. It is classified under the Therapeutic Goods Administration's framework as an unregistered substance. Compounding pharmacies in Australia have operated in a regulatory grey area regarding peptides; as of 2024–2025, the TGA has progressively tightened access to compounded peptides not on the Approved Active Ingredient Register.
Research use of AOD-9604 occurs through registered research institutions operating under appropriate ethics and scientific oversight frameworks.
Tesamorelin (trade name Egrifta in North America) is a synthetic analogue of growth hormone-releasing hormone (GHRH). Rather than directly supplying growth hormone or a GH fragment, Tesamorelin works upstream: it binds to GHRH receptors in the pituitary gland and stimulates the pituitary to produce and release endogenous growth hormone in a pulsatile, physiologically normal pattern.
This is mechanistically distinct from both AOD-9604 (which mimics a GH fragment directly) and from exogenous GH administration (which bypasses the hypothalamic-pituitary axis entirely). Tesamorelin preserves the feedback mechanisms of the GH axis while increasing GH output.
Tesamorelin's fat loss effects flow from its stimulation of endogenous GH secretion:
1. GH-driven lipolysis: Increased GH levels stimulate lipolysis in adipose tissue, particularly visceral adipose tissue (VAT) — the metabolically active fat surrounding the abdominal organs. Visceral fat is associated with elevated cardiovascular and metabolic disease risk and is notoriously resistant to standard caloric restriction.
2. IGF-1 mediation: Elevated GH from Tesamorelin increases liver-derived IGF-1, which in turn modulates body composition through multiple pathways affecting both fat and lean tissue.
3. Selectivity for visceral fat: This is Tesamorelin's most clinically significant characteristic. Research consistently shows that the compound preferentially reduces visceral adipose tissue rather than subcutaneous fat. In the population where it has been most extensively studied — HIV-infected individuals with antiretroviral-associated lipodystrophy — this selectivity is its primary therapeutic rationale.
Tesamorelin's research profile is substantially more developed than AOD-9604's, because it has an approved clinical application:
TGA and FDA approval context: Tesamorelin is FDA-approved in the United States specifically for the treatment of excess abdominal fat in HIV-positive patients with lipodystrophy — not for general obesity or weight loss. This distinction is important. The approval is for a defined, specific pathological condition.
Randomised controlled trial data: Multiple Phase III RCTs demonstrated significant reductions in visceral adipose tissue (VAT) in the approved population, with mean VAT reductions of 15–20% versus placebo over 26–52 weeks. These are robust, well-designed trials published in major journals including the New England Journal of Medicine.
General obesity application: Studies examining Tesamorelin in non-HIV adults have shown VAT-reducing effects, but the evidence base is smaller, effects are partially reversed upon discontinuation, and the compound is not approved for this indication anywhere. The 2023 GHRH agonist literature review published in Endocrine Reviews concluded that Tesamorelin's effects on visceral fat in healthy obese individuals are "promising but preliminary."
Side effects and considerations: Tesamorelin stimulates GH and IGF-1, which have potential implications for glucose regulation. Insulin resistance and elevations in fasting blood glucose have been observed in some trial participants. Any use requires monitoring of glycaemic parameters.
Tesamorelin (Egrifta) is not registered on the Australian Register of Therapeutic Goods (ARTG) for any indication as of 2026. It is not available through Australian pharmacies as a registered product. Research access within appropriate institutional frameworks follows separate regulatory pathways.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic analogue of the naturally occurring incretin hormone GLP-1, engineered for significantly extended half-life (approximately 1 week, enabling once-weekly dosing). It is the active compound in Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management).
Unlike AOD-9604 and Tesamorelin, semaglutide has a robust, well-replicated evidence base from large-scale Phase III trials, is registered by the TGA, and is available through the Australian healthcare system under defined conditions.
For a comprehensive overview of semaglutide's availability in Australia, see our articles on Ozempic in Australia and the Wegovy PBS listing.
Semaglutide works through the GLP-1 receptor system, which has multiple overlapping effects relevant to body weight:
1. Appetite suppression (central): GLP-1 receptors are expressed in the hypothalamus, brainstem, and areas of the brain involved in reward and food-seeking behaviour. Semaglutide activation of these receptors directly reduces appetite and food-seeking motivation — an effect that is genuinely central (brain-mediated) rather than simply peripheral satiety.
2. Gastric emptying reduction: GLP-1 receptor activation slows the rate at which food leaves the stomach. This extends the sensation of fullness after meals and blunts post-meal blood glucose spikes.
3. Insulin secretion and glucagon suppression: In glucose-dependent fashion, semaglutide increases insulin secretion and suppresses glucagon — effects that improve glycaemic control in type 2 diabetes and reduce the insulin spikes that can drive fat storage in susceptible individuals.
4. Peripheral adipose tissue effects: GLP-1 receptors are also expressed in adipose tissue, liver, and muscle. Preclinical and early clinical data suggest direct peripheral effects on lipid metabolism, though the relative contribution of these to overall weight loss versus the central appetite effects remains an area of active research.
The clinical evidence for semaglutide at weight-loss doses is among the strongest in pharmaceutical obesity medicine:
STEP trials (Wegovy): The STEP 1 trial (2021, New England Journal of Medicine) enrolled 1,961 adults with BMI ≥30 or ≥27 with comorbidities. After 68 weeks of once-weekly subcutaneous semaglutide 2.4mg, participants lost a mean 14.9% of body weight versus 2.4% with placebo — a difference of unprecedented magnitude for a pharmacological intervention versus lifestyle alone.
STEP 5: Demonstrated sustained efficacy to 104 weeks, with a mean weight loss of 15.2% maintained at 2 years.
SELECT trial (cardiovascular outcomes): Published in 2024 in the New England Journal of Medicine, the SELECT trial of 17,604 participants with established cardiovascular disease and overweight/obesity (without diabetes) found semaglutide reduced major adverse cardiovascular events by 20% versus placebo — establishing a benefit beyond weight loss.
Australian availability: Ozempic (semaglutide 0.5–2mg, for type 2 diabetes) is PBS-subsidised. Wegovy (semaglutide 2.4mg, for weight management) achieved TGA registration and subsequent PBS listing in 2025, making Australia one of the first countries with subsidised access for obesity treatment. See the Wegovy PBS listing article for eligibility and access details.
The "peptide weight loss stack" framing implies these compounds work through similar pathways and can be combined for additive effect. The reality is more nuanced.
| Feature | AOD-9604 | Tesamorelin | Semaglutide |
|---|---|---|---|
| Mechanism | GH fragment, direct lipolysis | GHRH analogue, stimulates pituitary GH release | GLP-1 receptor agonist, appetite + gastric emptying |
| Primary target | Adipose tissue (general) | Visceral adipose tissue (VAT) | Hypothalamus, GI tract, adipose |
| Endocrine axis | GH-related, partial | Hypothalamic-pituitary-GH axis | Incretin/enteroinsular axis |
| Human RCT evidence | Limited, mixed | Moderate (HIV lipodystrophy) | Extensive, large-scale |
| TGA registered? | No | No | Yes (Ozempic, Wegovy) |
| PBS listed? | No | No | Ozempic (diabetes), Wegovy (obesity — 2025) |
| IGF-1 effects | Minimal | Elevated | Minimal |
| Appetite effects | Not primary mechanism | Not primary mechanism | Primary mechanism |
| Muscle effects | Minimal (by design) | Modest anabolic (via IGF-1) | Limited, requires protein/exercise |
From a purely mechanistic standpoint, compounds working through the GH/GH-fragment pathway (AOD-9604, Tesamorelin) and GLP-1 pathway (Semaglutide) target different biological systems. In principle, they could produce additive or complementary effects:
However — and this is critical — theoretical mechanistic complementarity does not constitute clinical evidence. There are no published randomised controlled trials examining combinations of these compounds for weight management. The safety profile of such combinations, potential interactions (particularly regarding insulin sensitivity, IGF-1 levels, and glycaemic control), and whether additive effects materialise in humans rather than theoretical models are all unknown.
The concept of a "peptide stack" therefore currently exists at the level of preclinical reasoning and anecdotal reporting, not clinical evidence. This is an important distinction for anyone evaluating the research landscape.
The comparison between GH-axis peptides (AOD-9604, Tesamorelin) and GLP-1 receptor agonists (Semaglutide, Tirzepatide) is worth examining, because the mechanistic differences have meaningful implications for what types of excess adipose tissue each may address most effectively.
GLP-1 receptor agonists produce their weight loss primarily by reducing how much people eat — through appetite suppression that is both peripheral (gastric) and central (hypothalamic). The result is a reduction in total caloric intake that the body then expresses as fat loss from wherever fat is most readily mobilised.
The current generation of GLP-1 agonists (semaglutide, tirzepatide) produce average weight losses of 15–22% — substantially higher than previous anti-obesity medications. They do not, however, selectively target specific fat depots, and the proportion of weight lost from visceral versus subcutaneous fat roughly mirrors what would be expected from equivalent caloric restriction.
For a detailed mechanistic comparison of GLP-1 and dual GIP/GLP-1 agents, see our article on Tirzepatide versus Semaglutide in Australia.
Where GH-axis interventions (particularly Tesamorelin) may differ from GLP-1 agonists is in the demonstrated selectivity for visceral adipose tissue. VAT is metabolically distinct from subcutaneous fat: it has higher lipolytic activity, greater inflammatory signalling, and stronger associations with cardiovascular and metabolic disease risk.
If GH-axis stimulation can preferentially reduce VAT — as Tesamorelin appears to in the HIV lipodystrophy population — it targets a fat depot with disproportionately high health significance. Whether this selectivity translates meaningfully to the broader non-lipodystrophy population, and whether it produces health outcomes beyond what VAT percentage reduction predicts, are important open questions in the research.
Australia's Therapeutic Goods Administration (TGA) operates one of the world's more rigorous pharmaceutical regulatory systems. Understanding how it applies to these three compounds is essential for anyone navigating this space in an Australian context.
For most of the 2010s, Australian compounding pharmacies operated in a regulatory space that allowed them to produce and supply unregistered peptides — including AOD-9604, BPC-157, and growth hormone-releasing peptides — under various exemptions to standard TGA registration requirements.
From 2023 onwards, the TGA has progressively closed this pathway. Key developments:
An important distinction that is frequently conflated: research use of compounds by qualified researchers within institutional frameworks (universities, research institutions operating under ethics board approval) operates under a different regulatory pathway than clinical therapeutic use. Compounds that are not available for clinical prescription may nonetheless be available for legitimate preclinical or early clinical research through authorised channels.
Those with a professional research interest in these compounds — including their potential metabolic mechanisms — can explore AOD-9604 research sources through suppliers that operate within appropriate research-grade supply frameworks.
The distinction matters: obtaining and using these compounds outside legitimate research or clinical frameworks in Australia carries regulatory risk and, more importantly, health risk from unknown purity, dosing, and administration without medical monitoring.
Semaglutide is an entirely different regulatory category. Registered on the ARTG, TGA-approved, and now PBS-listed (Wegovy for obesity), it is accessed through the Australian healthcare system with a valid prescription from a qualified prescriber. It should not be conflated with research peptides — it is a regulated therapeutic product with a well-characterised safety profile from tens of thousands of trial participants.
The intersection of GH-axis peptides, GLP-1 agonists, and body composition is an active research area, with several directions worth tracking:
Early-stage research is examining whether GH-axis stimulation and GLP-1 agonism can produce complementary effects on body composition — specifically, whether GLP-1-driven caloric reduction combined with GH-axis lipolytic stimulation might produce superior fat loss with better lean mass preservation than either alone. This is currently at preclinical and early Phase I stages; no robust human data exists.
One concern with the dramatic weight loss produced by GLP-1 agonists is the proportion of that loss that comes from lean mass rather than fat. Preliminary data suggests 25–39% of total weight lost with semaglutide may come from lean tissue — potentially more than the 20–30% seen with lifestyle-only interventions. This has driven research interest in whether adjunct interventions (high protein intake, resistance training, or potentially muscle-preserving peptides) can shift this ratio favourably.
Research into next-generation GH secretagogues — compounds that stimulate GH release through GHRH receptors, ghrelin receptors, or alternative pituitary pathways — continues, with the goal of achieving visceral fat selectivity more reliably than existing compounds. Several are in preclinical or early Phase I stages as of 2026.
The broader context for metabolic peptide research includes investigation of compounds across inflammation, mitochondrial function, insulin signalling, and adipogenesis pathways. This field intersects with the growing pharmacological interest in metabolic disease beyond simple caloric imbalance. For a broader view of how GLP-1 mechanisms interact with current Australian prescribing, see our overview of how GLP-1 agonists work.
AOD-9604 is not TGA-approved as a therapeutic product and is not available for clinical use outside registered trials or specific TGA-authorised pathways. The TGA's tightened compounding regulations from 2023 onwards have significantly restricted its availability through Australian compounding pharmacies. Research use within appropriately authorised institutional frameworks is subject to different regulatory considerations. Seeking and using unregistered compounds for personal use outside medical supervision carries both regulatory and health risks.
Tesamorelin stimulates the pituitary gland to produce growth hormone naturally in a pulsatile pattern — preserving the body's own feedback mechanisms. Exogenous GH administration bypasses these mechanisms entirely, suppressing natural GH production and producing continuous (rather than pulsatile) GH elevation, which carries different risk profiles. Tesamorelin is considered to have a more physiologically appropriate GH stimulation pattern, but it still produces elevated IGF-1 and GH levels that require monitoring.
No combination of semaglutide with AOD-9604 or Tesamorelin has been studied in registered clinical trials. Any potential interaction — including effects on glycaemic control, IGF-1 levels, or cardiovascular function — is unknown. This is not a combination that any regulatory body has evaluated for safety or efficacy, and it should not be pursued outside a supervised clinical trial context.
These terms refer to the same peptide sequence from different framing. HGH Fragment 176-191 describes the specific amino acid positions (176 through 191) of the human growth hormone molecule that the peptide replicates. AOD-9604 is the pharmaceutical research designation given to this fragment during its development by Metabolic Pharmaceuticals. They are chemically identical. See our dedicated HGH Fragment 176-191 article for more detail.
Semaglutide (Wegovy) is TGA-approved and PBS-listed for weight management in Australia for eligible patients — specifically those with BMI ≥30 or ≥27 with a weight-related comorbidity. Tirzepatide (Mounjaro) is available on prescription for type 2 diabetes and has been studied for obesity (SURMOUNT trials). No GH-axis peptide (including AOD-9604 or Tesamorelin) is approved for weight management in Australia.
The three compounds most commonly discussed in the context of a "peptide weight loss stack" — AOD-9604, Tesamorelin, and Semaglutide — share the broad goal of reducing adipose tissue but differ fundamentally in mechanism, evidence quality, regulatory status, and availability.
Semaglutide has the strongest evidence base, the clearest regulatory pathway, and the greatest clinical impact in the current Australian landscape. Its limitations — cost, access, side effects, and the lean mass question — are real but manageable within a medically supervised context.
AOD-9604 and Tesamorelin represent scientifically interesting avenues of GH-axis research with mechanistically distinct fat-targeting properties — particularly Tesamorelin's selectivity for visceral adipose tissue. But the human clinical evidence remains limited relative to the GLP-1 agonist class, and Australian regulatory realities constrain access outside research contexts.
The most rigorous framing of this space: these are not interchangeable tools in a consumer weight loss protocol, but rather distinct research-stage and approved compounds at very different stages of clinical and regulatory development. Understanding that distinction — and engaging with the research accordingly — is what separates informed inquiry from uncritical enthusiasm.
References: Heffernan MA et al., Journal of Endocrinology. Falutz J et al., New England Journal of Medicine (Tesamorelin Phase III). Wilding JPH et al., NEJM (STEP 1 trial, semaglutide). Lincoff AM et al., NEJM (SELECT trial). Endocrine Reviews systematic review (2023). Rubino DM et al., JAMA (STEP 4). Australian Therapeutic Goods Administration: Compounding peptides guidance 2023–2024. ARTG entry for Ozempic and Wegovy. Monash University Metabolic Pharmaceuticals research record. TGA Regulatory Framework for Biologicals and Peptides (2024 update).
A research-backed explainer on orforglipron (Foundayo) — the first oral small-molecule GLP-1 receptor agonist approved for weight loss, why no-restriction dosing matters, what the ATTAIN trials showed, and how it compares to injectables and oral semaglutide.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.
Cagrilintide is a once-weekly long-acting amylin analog, and Cagrisema combines it with semaglutide. This guide covers the REDEFINE Phase 3 trial results, how amylin co-agonism works, why the headline weight loss disappointed market expectations despite being clinically significant, and what the Australian regulatory path looks like.